Table 3.

Evaluation of response to UDCA therapy in patients with PBC

UDCA-response criteria	Time (months)	Definition of response
Barcelona [115]	12	> 40% decrease or normalization of ALP
Mayo [116]	6	ALP < 2 × ULN
Paris I [111]	12	ALP ≤ 3.0 × ULN and AST ≤ 2.0 × ULN and normalization of bilirubin
Rotterdam [117]	12	Normalization of abnormal bilirubin and/or albumin
Ehime [118]	6	≥ 70% decrease or normalization of GGT
Toronto [119]	24	ALP ≤ 1.67 × ULN
Paris II [121]	12	ALP and AST ≤ 1.5 × ULN and normalization of bilirubin
Risk scoring systems		Included parameters
GLOBE [123]	12	Age at diagnosis. ALP, bilirubin, albumin and platelet count at 12 month
UK-PBC [124]	12	Baseline albumin and platelet count ALP, bilirubin and AST (or ALT) at 12 month

UDCA ursodeoxycholic acid, ALP alkaline phosphatase, ULN upper limit of normal, AST aspartate aminotransferase, ALT alanine aminotransferase